DD298053A5 - Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides - Google Patents

Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides Download PDF

Info

Publication number
DD298053A5
DD298053A5 DD90344215A DD34421590A DD298053A5 DD 298053 A5 DD298053 A5 DD 298053A5 DD 90344215 A DD90344215 A DD 90344215A DD 34421590 A DD34421590 A DD 34421590A DD 298053 A5 DD298053 A5 DD 298053A5
Authority
DD
German Democratic Republic
Prior art keywords
peptide
thymopentin
peptides
amino acid
formulations
Prior art date
Application number
DD90344215A
Other languages
German (de)
English (en)
Inventor
Gideon Goldstein
Tapan Audhya
Original Assignee
������@�������������@����������k���Kk��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ������@�������������@����������k���Kk�� filed Critical ������@�������������@����������k���Kk��
Publication of DD298053A5 publication Critical patent/DD298053A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DD90344215A 1989-09-28 1990-09-26 Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides DD298053A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41384189A 1989-09-28 1989-09-28

Publications (1)

Publication Number Publication Date
DD298053A5 true DD298053A5 (de) 1992-02-06

Family

ID=23638883

Family Applications (1)

Application Number Title Priority Date Filing Date
DD90344215A DD298053A5 (de) 1989-09-28 1990-09-26 Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides

Country Status (14)

Country Link
EP (1) EP0420649A3 (fr)
JP (1) JPH04502017A (fr)
AU (1) AU6446790A (fr)
BR (1) BR9006934A (fr)
CA (1) CA2026149A1 (fr)
DD (1) DD298053A5 (fr)
HU (1) HUT59013A (fr)
IE (1) IE903475A1 (fr)
IL (1) IL95663A0 (fr)
IT (1) IT1240314B (fr)
NZ (1) NZ235324A (fr)
PT (1) PT95451A (fr)
WO (1) WO1991004743A1 (fr)
ZA (1) ZA907492B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036050A (en) * 1989-01-12 1991-07-30 Immunobiology Research Institute, Inc. Compositions containing thymopentin for topical treatment of skin disorders
JP3537440B2 (ja) * 1993-12-17 2004-06-14 持田製薬株式会社 可溶性トロンボモジュリンを長期保存安定化させる方法
CA2192725C (fr) 1995-12-28 2004-04-20 Kenji Tsujihara Derives de la camptothecine
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PL2107069T3 (pl) 2003-08-05 2013-06-28 Novo Nordisk As Nowe pochodne insuliny
DE102004011663B4 (de) 2004-03-10 2006-04-27 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
WO2008152106A1 (fr) 2007-06-13 2008-12-18 Novo Nordisk A/S Formulation pharmaceutique contenant un dérivé d'insuline
CN109010254A (zh) 2008-08-15 2018-12-18 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CA2742659C (fr) * 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Composition aqueuse contenant de l'hormone folliculostimulante
JP2013501071A (ja) 2009-08-06 2013-01-10 アイロンウッド ファーマシューティカルズ， インコーポレイテッド リナクロチドを含む処方物
TWI609698B (zh) * 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
EP2536742B1 (fr) 2010-02-17 2017-07-19 Ironwood Pharmaceuticals, Inc. Traitements de troubles gastro-intestinaux
ES2919136T3 (es) 2010-08-11 2022-07-22 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
KR101673654B1 (ko) 2011-04-20 2016-11-07 산도즈 아게 융합 단백질 TNFR:Fc의 안정한 제약 액체 제제
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatment of gastrointestinal disorders
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
WO2013059410A1 (fr) 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Préparations d'étanercept stabilisées avec du xylitol
EA031324B1 (ru) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
CN105012232B (zh) * 2015-08-14 2017-09-05 北京世桥生物制药有限公司 一种胸腺五肽注射液及其制作方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2023017537A1 (fr) 2021-08-12 2023-02-16 Celagenex Research (India) Pvt. Ltd. Composition peptidique orale perméable au tractus gastro-intestinal à base d'huile algale

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190646A (en) * 1975-11-11 1980-02-26 Sloan-Kettering Institute For Cancer Research Polypeptide compositions and methods
JPS57169425A (en) * 1981-04-10 1982-10-19 Eisai Co Ltd Composition and method for preventing adsorption of secretin
EP0082481B2 (fr) * 1981-12-23 1990-09-12 Schering Corporation Compositions stabilisées d'interféron alpha et leur préparation
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
US4749690A (en) * 1986-01-27 1988-06-07 Ortho Pharmaceutical Corporation Treatment of allergy with thymopentin
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator

Also Published As

Publication number Publication date
HUT59013A (en) 1992-04-28
JPH04502017A (ja) 1992-04-09
EP0420649A3 (en) 1991-07-31
AU6446790A (en) 1991-04-28
IT9019421A0 (it) 1990-02-20
HU907939D0 (en) 1991-08-28
IT1240314B (it) 1993-12-07
BR9006934A (pt) 1991-10-22
IT9019421A1 (it) 1991-03-29
CA2026149A1 (fr) 1991-03-29
PT95451A (pt) 1991-05-22
WO1991004743A1 (fr) 1991-04-18
ZA907492B (en) 1991-10-30
IL95663A0 (en) 1991-06-30
EP0420649A2 (fr) 1991-04-03
NZ235324A (en) 1992-07-28
IE903475A1 (en) 1991-04-10

Similar Documents

Publication Publication Date Title
DD298053A5 (de) Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides
DE69334134T2 (de) Wässrige Formulierung enthaltend Menschliches Wachstumshormon
DE68918853T2 (de) Formulierung von menschlichen wachstumshormonen.
DE3520228C2 (de) Wasserlösliche bioaktive Trockenfeststoffzusammensetzung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
DE60033437T2 (de) Glp-2 enthaltende formulierungen
DE69102465T2 (de) Stabilisierte Gonadotropin enthaltende Zubereitungen.
EP1517697B1 (fr) Preparations acides d'insuline ayant une meilleure stabilite
DE69329367T3 (de) Wachstumshormon-enthaltende proteinformulierung
EP1648485B1 (fr) Formulation destinee a un agent pharmaceutique proteique ne contenant pas d'albumine serique humaine ajoutee (hsa)
DE69816409T2 (de) Kristallines Parathyroidhormon
DE69431562T2 (de) Pharmazeutische formulierungen enthaltend nervenwachstumsfaktor
DE69103755T2 (de) Wachstumshormonkristalle und verfahren zu deren herstellung.
DE69825137T2 (de) Liposomale Erythropoietin-Dispersion
DE69230672T2 (de) Gonadotropin, das pharmazeutische zusammensetzungen mit sucrose stabilisator enthält
CH693019A5 (de) Insulin-Analogon-Formulierungen.
EP0674524A1 (fr) Preparations pharmaceutiques de g-csf lyophilisees stables
DE10355251A1 (de) Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE69827357T2 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
EP2451471A1 (fr) Préparations d'insuline à effet retard
DE202014011208U1 (de) C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind
DE69919533T2 (de) Proteinhaltige arzneimittel
DE69420872T2 (de) Hgh enthaltende pharmazeutische zubereitungen
DD289470A5 (de) Verfahren zur herstellung eines arzneimittels mit einem gehalt an gamma-interferon
DE69417397T2 (de) Lösung, die igf-1 enthält
DE69313444T2 (de) IL-6 ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN stabilisiert mit einem nicht-reduzierenden Zucker

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee